About Bioharmony Therapeutics
Bioharmony Therapeutics is a Healthcare company based in New York (United States) founded in 2016. It develops lysin-based therapeutics to treat bacterial infectious diseases. It operates on a B2B model. Bioharmony Therapeutics has raised $100 thousand across 1 funding round from investors including Accelerate NY Seed Fund. The company has 1 employees. Its website bioharmonytherapeutics.com draws about 681 thousand monthly visits. Its focus areas include Biotechnology, Pharmaceuticals and Therapeutics. Its competitors include Insmed, Affinivax, Adaptive Phage Therapeutics, Eligo Bioscience and Lodo Therapeutics and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
Bioharmony Therapeutics, founded in 2016 in New York, United States, focuses on providing healthcare solutions, advancing biotech innovations, producing pharmaceutical products, and therapeutics. Develops lysin-based therapeutics to treat bacterial infectious diseases. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
- Headquarters New York, United States
- Employees 1
- SectorsHealthcare
- Website bioharmonytherapeutics.com
- Social X
- Total Equity Funding$100K (USD)
in 1 rounds
- Latest Funding Round$100K (USD), Seed
Dec 2017
- Investors
- Employee Count1
Funding Insights of Bioharmony Therapeutics
Bioharmony Therapeutics has successfully raised a total of $100K through 1 strategic funding round. The most recent funding activity was a Seed round of $100 thousand completed in December 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $100,000
- Total Rounds 1
- Last Round Seed — $100,000
- First Round $100,000
(Dec 2017)
- Investors Count 1
All 1 funding rounds of Bioharmony Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2017 | $100,000 | Seed | – | – |
1 investors in total: 1 institutional.
Investors in Bioharmony Therapeutics
Bioharmony Therapeutics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Accelerate NY Seed Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | anyseedfund.com | - |
Investor details for Bioharmony Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Bioharmony Therapeutics
2 people are tracked at Bioharmony Therapeutics (1 in board & advisors, 1 in team); the tracked headcount is 1.
| Name | Role | Group |
|---|---|---|
Vincent A. Fischetti | Scientific Advisor | Board & advisors |
Chris Garabedian | Chairman | Team |
Complete people profiles for Bioharmony Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Bioharmony Therapeutics
2 dated milestones of Bioharmony Therapeutics across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Bioharmony Therapeutics is founded.
- Funding First funding round of $100K.
Competitors of Bioharmony Therapeutics
Bioharmony Therapeutics has 9 listed competitors in our database, 8 of them funded. They include Insmed, Affinivax, Adaptive Phage Therapeutics, Eligo Bioscience and Lodo Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insmed.com | 1999 | Bridgewater, United States | – | 912 | Developer of small molecule inhibitors for rare lung diseases | |
| affinivax.com | 2013 | Cambridge, United States | $359.49M | 132 | Technology-based conjugate vaccines against infectious diseases are developed. | |
| aphage.com | 2016 | Bethesda, United States | $107.87M | 78 | Therapies for multi-drug resistant infections are developed using bacteriophages. | |
| eligo.bio | 2014 | Paris, France | $52.26M | – | In vivo gene editing technology is developed for microbiome modulation. | |
| lodotherapeutics.com | 2015 | New York, United States | $19.87M | 24 | Developer novel therapeutics to treat resistant infectious diseases and cancers using AI | |
| biomx.com | 2015 | Ness Ziona, Israel | $56M | – | Microbiome therapeutics are developed for dysbiosis-linked diseases. | |
| symbiomix.com | 2012 | Newark, United States | $66.55M | – | Late-stage biopharma antibiotics for gynecological infections are developed. | |
| spybiotech.com | 2017 | Oxford, United Kingdom | $38.6M | 10 | Developer of vaccines for bacterial infections and cancer by using proprietary protein superglue technology | |
| elusys.com | 1999 | Montville, United States | $50M | 15 | Antibody therapeutics for anthrax and infectious diseases are developed. |
Detailed competitors of Bioharmony Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Bioharmony Therapeutics
The website of Bioharmony Therapeutics (bioharmonytherapeutics.com) receives about 680.7K visits a month.
- Monthly visits680.7K
▼ 6.7% vs previous month
Websites whose visitors overlap most with Bioharmony Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| falconebiz.com | 100% | 959.8K | #63,970 | View details | |
| tofler.in | 97% | 556K | #105,509 | View details | |
| zaubacorp.com | 96% | 4.9M | #12,689 | View details | |
| tracxn.com | 92% | 2.9M | #16,597 | View details | |
| indiafilings.com | 90% | 2.1M | #29,959 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Bioharmony Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
10 companies that operate in the same segment as Bioharmony Therapeutics (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bioharmony Therapeutics
Complete news archive for Bioharmony Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bioharmony Therapeutics
Bioharmony Therapeutics was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Bioharmony Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Bioharmony Therapeutics is a funded company, having raised a total of $100K across 1 funding round to date. The company's 1st funding round was a Seed of $100K, raised on Dec 2017.
Bioharmony Therapeutics has 1 employees.
Bioharmony Therapeutics, founded in 2016 in New York, United States, focuses on providing healthcare solutions, advancing biotech innovations, producing pharmaceutical products, and therapeutics. Develops lysin-based therapeutics to treat bacterial infectious diseases. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
Bioharmony Therapeutics's top competitors include Insmed, BiomX and Eligo Bioscience.
Bioharmony Therapeutics has 1 investor. Key investors include Accelerate NY Seed Fund.
The website of Bioharmony Therapeutics receives about 681 thousand visits a month.